Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial

Liles, Elizabeth; Coronado, Gloria D.; Perrin, Nancy; Harte, Amy Howell; Nungesser, Raymond; Quigley, Neil B.; Potter, Nicholas; Weiß, Günter; Koenig, Thomas; deVos, Theo

doi:10.1016/j.ctarc.2016.12.004

Cited by 33 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…gov, ID NCT02251782): The FDA requested a final study to determine if patients would accept a blood based test. In the multicenter randomized ADMIT trial, acceptance of Epi proColon blood testing was 99.5%, compared with 88.1% for FIT, demonstrating a high degree of acceptance for the blood test [37]. In this study, 67% of patients with a positive test scheduled a follow-up diagnostic colonoscopy, and of those completing colonoscopy, 59% had a finding of a lesion (adenoma, polyp or other) requiring follow-up pathology.…”

Section: Epi Procolon Clinical Trialsmentioning

confidence: 90%

“…In a test choice trial in Germany, 83% of patients who refused a screening colonoscopy chose to be screened with the blood test, and 15% opted for a stool test, for a combined 98% coverage by non-invasive testing [39]. Furthermore in the randomized ADMIT trial in the US described above, 99.5% of patients who had previously not completed screening after at least two recommendations, proceeded to be screened with the blood test [37]. In this study, for the patients with a positive test, 67% scheduled a diagnostic colonoscopy within 3 months, and for those patients with a diagnostic colonoscopy, 59% had a finding resulting in a polypectomy or biopsy.…”

Section: Journal Of Clinical Epigenetics Issn 2472-1158mentioning

confidence: 99%

See 1 more Smart Citation

Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA

deVos¹,

Molnár²

2017

J Clin Epigenet

Self Cite

View full text Add to dashboard Cite

Section: Epi Procolon Clinical Trialsmentioning

confidence: 90%

Section: Journal Of Clinical Epigenetics Issn 2472-1158mentioning

confidence: 99%

Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA

deVos¹,

Molnár²

2017

J Clin Epigenet

Self Cite

View full text Add to dashboard Cite

“…Sensitivity to discriminate between CRC and non-CRC was 73%, and specificity was 82%. Interestingly, a randomized controlled twosite trial with average-risk adults overdue for screening (NCT02251782) showed that Epi proColon boasts better patient adherence to screening than FIT (N = 413, 99.5% vs 88.1%) [162].…”

Section: Translational Statusmentioning

confidence: 99%

The Translational Status of Cancer Liquid Biopsies

Bratulić

Gatto

Nielsen

2019

Regen. Eng. Transl. Med.

View full text Add to dashboard Cite

Precision oncology aims to tailor clinical decisions specifically to patients with the objective of improving treatment outcomes. This can be achieved by leveraging omics information for accurate molecular characterization of tumors. Tumor tissue biopsies are currently the main source of information for molecular profiling. However, biopsies are invasive and limited in resolving spatiotemporal heterogeneity in tumor tissues. Alternative non-invasive liquid biopsies can exploit patient's body fluids to access multiple layers of tumor-specific biological information (genomes, epigenomes, transcriptomes, proteomes, metabolomes, circulating tumor cells, and exosomes). Analysis and integration of these large and diverse datasets using statistical and machine learning approaches can yield important insights into tumor biology and lead to discovery of new diagnostic, predictive, and prognostic biomarkers. Translation of these new diagnostic tools into standard clinical practice could transform oncology, as demonstrated by a number of liquid biopsy assays already entering clinical use. In this review, we highlight successes and challenges facing the rapidly evolving field of cancer biomarker research. Lay SummaryPrecision oncology aims to tailor clinical decisions specifically to patients with the objective of improving treatment outcomes. The discovery of biomarkers for precision oncology has been accelerated by high-throughput experimental and computational methods, which can inform fine-grained characterization of tumors for clinical decision-making. Moreover, advances in the liquid biopsy field allow non-invasive sampling of patient's body fluids with the aim of analyzing circulating biomarkers, obviating the need for invasive tumor tissue biopsies. In this review, we highlight successes and challenges facing the rapidly evolving field of liquid biopsy cancer biomarker research.

show abstract

“…In addition, compliance with CRC screening recommendations is low, and only about 40% of the population for which screening is recommended will undergo testing . A more patient friendly and minimally invasive blood‐based test would certainly increase adhesion …”

Section: Introductionmentioning

confidence: 99%

“…5 A more patient friendly and minimally invasive bloodbased test would certainly increase adhesion. 6,7 There is some evidence that cancer cells establish a profitable interplay with bystander cells of their microenvironment, to receive help for growth and metastasis, nutrition and protection from immune recognition. 8 The cross talk between tumor and stroma occurs through the modulation/release of nucleic acid messengers (DNA, mRNA and microRNAs [miRNAs]) and soluble factors acting locally and at a distance to modify the cells' behavior.…”

Section: Introductionmentioning

confidence: 99%

Plasma miRNA‐based signatures in CRC screening programs

Zanutto

Ciniselli

Belfiore

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood based, to increase early CRC identification. MicroRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT‐positive (FIT+) subjects in an Italian CRC screening program, we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real‐time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort [EVC], 1121 cases). For each endoscopic lesion (low‐grade adenoma [LgA], high‐grade adenoma [HgA], cancer lesion [CL]), specific signatures were identified in the IVC and confirmed on the EVC. A two‐miRNA‐based signature for CL and six‐miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the receiver operating characteristic curve (95% confidence interval) of the signatures were 0.644 (0.607–0.682), 0.670 (0.626–0.714) and 0.682 (0.580–0.785) for LgA, HgA and CL, respectively. A miRNA‐based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most.

show abstract

Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial

Cited by 33 publications

References 27 publications

Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA

Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA

The Translational Status of Cancer Liquid Biopsies

Plasma miRNA‐based signatures in CRC screening programs

Contact Info

Product

Resources

About